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Effects of tissue inhibitor of metalloproteinase 2
deficiency on aneurysm formation
Wanfen Xiong, MD, PhD,a Rebecca Knispel, BS,a Jason Mactaggart, MD,a and B. Timothy Baxter,
MDab, Omaha, Neb
Objective: Matrix metalloproteinase (MMP)-2 has been shown to play a pivotal role in aortic aneurysm formation. Its
activation requires formation of a trimolecular complex of MMP-2, tissue inhibitor of metalloproteinase-2 (TIMP-2),
and membrane type 1 (MT1)-MMP, which is attached to the cell surface. At higher concentrations, TIMP-2 becomes an
inhibitor of MMP-2. Thus, TIMP-2 could both augment and inhibit matrix degradation. This study was undertaken to
define the net effect of TIMP-2 on matrix destruction and aneurysm formation.
Methods: The abdominal aortas of wild-type and TIMP-2–deficient (TIMP-2/) mice were exposed to 0.25 mol/L
CaCl2 or 0.9%NaCl for 15 minutes after laparotomy. Aortic diameters were measured before treatment and 6 weeks after
aneurysm induction. In addition, aortic tissues were studied for MMP-2 activation by zymography, and matrix structure
was studied by connective tissue staining.
Results: The aortic diameter increased in both wild-type and TIMP-2/mice. The increase in the TIMP-2/mice was
significantly smaller after CaCl2 treatment (51%  3%) compared with the diameter of wild-type mice (67%  4%).
Connective staining of aortic sections from the CaCl2-treated mice revealed disruption and fragmentation of the medial
elastic lamellae in both wild-type and TIMP-2/ mice. Zymographic analysis showed that active MMP-2 levels were
decreased in TIMP-2/ aortas compared with wild-type mice.
Conclusions: Targeted deletion of TIMP-2 results in attenuation of aneurysm development. Despite its name as an
inhibitor of MMPs, TIMP-2 promotes aortic enlargement in vivo, presumably through its role as a cofactor in the
activation of MMP-2. (J Vasc Surg 2006;44:1061-6.)
Clinical Relevance: Abdominal aortic aneurysmal (AAA) disease is a potentially fatal disorder that screening studies have
detected in 2% to 9% of the general population. Medical therapy designed to inhibit the progression of small aneurysms
includes control of hypertension and smoking cessation; neither of these measures is of proven benefit. Effective and
directed medical treatments for small AAAs await elucidation of key etiologic factors. Understanding precisely which
molecules mediate AAA development, and blocking the activity of these molecules, could lead to important new therapies.
Through our research, we have found that tissue inhibitor of metalloproteinase (TIMP)-2 has a role in this process in an
experimental model of aortic aneurysms. We believe that TIMP-2 promotes aortic enlargement in vivo by activating
matrix metalloproteinase 2.Abdominal aortic aneurysms (AAA) represent a com-
plicated and dynamic remodeling process in which the
aorta enlarges to a point at which rupture may occur. The
structural matrix proteins, collagen and elastin, are durable
and relatively resistant to degradation by all but a few
specific enzymes. Studies of human AAA tissues and animal
models of AAA consistently show increased production of
matrix metalloproteinases (MMPs),1,2 a family of proteases
capable of efficiently degrading matrix macromolecules. In
addition, aneurysm tissue exhibits altered tissue inhibitor/
MMP ratios3,4 in association with disruption of the orderly
lamellar structure of the aorta.5
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doi:10.1016/j.jvs.2006.06.036To date, the MMP family is composed of 24 members
classified into 5major subfamilies: collagenases, gelatinases,
elastase, stromelysins, and membrane-type MMPs (MT-
MMPs) (Table I). MMPs are typically synthesized as latent
zymogens and require proteolytic cleavage to achieve their
catalytic activity. This posttranslational modification is one
of the key steps in modulating local matrix destruction by
MMPs. The extracellular activation of MMP-2, one of the
MMPs essential for aneurysm formation, occurs through
the formation of a trimolecular complex formed on the cell
surface. MMP expression and activity are controlled by the
endogenous physiological tissue inhibitors of MMPs
(TIMPs). It is believed that disruption of the MMP/TIMP
balance is responsible for the excessive elastic degradation
seen in AAA. The TIMP family currently includes four
different members (TIMP-1 to TIMP-4).6-9 TIMP-1 is a
known specific inhibitor of MMP-1 and MMP-9. Deletion
of the TIMP-1 gene results in increased and continued
progression of aneurysm formation in a mouse aortic aneu-
rysm model.10,11 At higher levels, TIMP-2 selectively in-
hibits MMP-2 gelatinolytic activity in vitro.12 At low con-
centrations, TIMP-2 augments pro–MMP-2 activation by
the formation of a trimolecular complex composed of
1061
JOURNAL OF VASCULAR SURGERY
November 20061062 Xiong et alMT1-MMP, TIMP-2, and pro–MMP-2.13,14 However,
the net effect of TIMP-2 on matrix destruction in vivo
(promoter vs inhibitor) has not yet been defined. We
hypothesize that TIMP-2 plays a key role in MMP-2 acti-
vation and promotes, rather than inhibits, aneurysm forma-
tion through activation of MMP-2. We used TIMP-2–
deficient mice and a murine aneurysm model to test this
hypothesis.
METHODS
Mice. The homozygous TIMP-2 gene knockout
(TIMP-2/) mice were obtained from Cornell Univer-
sity, New York, NY (Dr Paul D. Soloway). These mice were
back-crossed seven times into a C57BL/6 background
such that they shared 99.22% genetic similarity with
C57BL/6. The homozygote TIMP-2/mice breed nor-
mally, and all were bred from the homozygous mice ob-
tained from and genotyped by Dr Soloway. The phenotype
was verified in our laboratory by using reverse zymography,
which confirmed the absence of TIMP-2 (Fig 1). The
appropriate control mice, the standard C57BL/6 mice,
were purchased fromThe Jackson Laboratory (Bar Harbor,
Me). All experiments were performed in accordance with
the guidelines of the University of Nebraska Medical Cen-
ter Animal Care Committee for the use and care of labora-
tory animals. All mice were maintained in a pathogen-free
animal facility.
Aneurysm induction model. TIMP-2/ mice and
37.1
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Fig 1. Reverse-zymographic analysis of tissue inhibitor of metal-
loproteinases (TIMPs). Aortic proteins from wild-type (WT) and
TIMP-2/mice were extracted and separated by electrophoresis
on a 17% sodium dodecylsulfate-polyacrylamide gel electrophore-
sis containing 0.8% gelatin and 0.16 g/mL matrix metallopro-
teinase 2. The gelatin was preserved by TIMP-1 and TIMP-2
(indicated by arrows). TIMP-2 was not expressed by the TIMP-
2/mice. The gel is representative of three separate experiments.
Table I. Matrix metalloproteinases
MMP family Members
Gelatinase MMP-2, MMP-9
Stromolysins MMP-3
Elastase MMP-12
Collagenase MMP-1, MMP-13
Membrane type MT-MMP (1-4)
MMP, Matrix metalloproteinase; MT, membrane type.their controls (aged 8 weeks) underwent surgery as de-scribed previously.2,15 Briefly, the mice were anesthetized
with intraperitoneal 2,2,2-tribromoethanol (Avertin;
Sigma, St Louis, Mo) at 200 mg/kg before undergoing
laparotomy. The abdominal aorta between the renal arter-
ies and bifurcation of the iliac arteries was isolated from the
surrounding retroperitoneal structures. The diameter of
the aorta was measured in triplicate midway between the
renal artery origin and iliac artery bifurcation. After baseline
measurements, 0.25 mol/L CaCl2 was applied to the ex-
ternal surface of the aorta for 15 minutes. The aorta was
then rinsed with 0.9 % sterile saline, and the incision was
closed. NaCl (0.9%) was substituted for CaCl2 in sham
control mice. Six weeks later, the mice underwent laparot-
omy and dissection. Measurements were repeated at the
same location in the mid infrarenal aorta. Typically, there
was diffuse, homogeneous dilatation of the infrarenal aorta
in wild-type mice and, to a lesser extent, in the knockout
mice. The aorta was collected for zymographic analysis of
MMP proteins. The aorta was perfusion-fixed with 10%
neutral buffered formalin for histologic studies.
Histologic analysis. After perfusion-fixation, abdom-
inal aortic tissues were embedded in paraffin and cut into
4-m sections. Standard Masson trichrome staining was
performed. The slides were examined and photographed
with light microscopy (Kodak, Tokyo, Japan; magnifica-
tion, 20).
Gelatin zymography. Aortic proteins were extracted
as previously described.2 The protein concentration for
aortic proteins was standardized with Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, Calif). Gelatin zymogra-
phy was performed as described previously by Longo et al2
with 0.8% gelatin in a 10% sodium dodecylsulfate-
polyacrylamide gel. The molecular sizes of gelatinolytic activ-
ities were determined by using protein standards (Bio-Rad).
Reverse zymography. Aortic proteins were separated
by electrophoresis on 17% sodium dodecylsulfate-
polyacrylamide gel copolymerized with 0.8% gelatin and
0.16 g/mL MMP-2. After electrophoresis, the sodium
dodecylsulfate was removed from the gel by washing in
2.5% Triton X-100 for 2 hours. The gels were incubated at
37°C overnight in development buffer (50 mmol/L Tris-
HCl [pH 7.5], 5 mmol/L CaCl2, 1 mol/L ZnCl2, and 3
mmol/L NaN3), stained with 0.5% Coomassie brilliant
blue G-250 for 20 minutes, and destained in gel-destaining
buffer (40% methanol and 10% glacial acetic acid) until the
background was clear.
Reverse transcription-polymerase chain reaction.
Aortas from wild-type mice were collected at 6 weeks after
treatment with 0.9% NaCl or 0.25 mmol/L CaCl2. Total
RNA was extracted by using TRIzol reagent (Invitrogen,
Carlsbad, CA), and TIMP-2 expression was analyzed by
reverse transcription-polymerase chain reaction. First-
strand complementary DNAs were synthesized by reverse
transcription by using the first-strand synthesis kit (Invitro-
gen) primed with oligo(dT)20. The polymerase chain reac-
tion was performed by using Platinum Taq DNA polymer-
ase (Invitrogen) and primers specific for TIMP-2.
Polymerase chain reaction products were analyzed by using
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expressed housekeeping gene -actin was used.
Statistical analysis. Measurements of aortic diameter
and gelatinolytic activity are expressed as mean  SE. A
paired Student t test was used to compare original and final
diameters. Analysis of variance (ANOVA) was used to
compare final aortic diameter between groups. Statistical
significance was accepted at P  .05.
RESULTS
Aortic diameter change. Increased expression of
MMP-2 has been observed in AAA tissue.16,17 Transgenic
mice with no MMP-2 expression are resistant to elastin
degradation and the formation of AAA.2 There is evidence
that TIMP-2 is required for efficient activation of pro–
MMP-2 in vitro.18 In addition, messenger RNA levels of
TIMP-2 were significantly increased in aneurysmal CaCl2-
treated aorta relative to non–aneurysmal NaCl–treated
controls (Fig 2). Therefore, we hypothesized that TIMP-2
deficiency would decrease MMP-2 activation and inhibit
aneurysm formation in a murine AAAmodel. Alternatively,
deficiency of TIMP-2 could lead to promotion of AAA if
the primary effect, in vivo, is inhibition of MMP-2 activity.
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Fig 2. Expression of tissue inhibitor of metalloproteinase
(TIMP)-2. Six weeks after 0.9% NaCl or 0.25 mol/L CaCl2
treatment, wild-type mouse aortas were harvested. Total RNA
from each aorta was extracted, and TIMP-2 messenger RNA
(mRNA) levels were examined by reverse transcription-
polymerase chain reaction. Alpha actin was used as the internal
standard. The gel is representative of three separate experiments.
The TIMP-2 expression is normalized to -actin expression. The
relative levels of TIMP-2 mRNA in CaCl2-treated aorta to NaCl-
treated aorta are expressed in the bar graph.To test this hypothesis, TIMP-2/ mice and wild-typecontrol mice of the same background were tested for their
response to CaCl2 aneurysm induction. Six weeks after
periaortic application of CaCl2, wild-type control mice
showed a 67% 4% increase in aortic diameter after CaCl2
treatment. The aortic diameter of the TIMP-2/ mice
also increased significantly (51%  3%). The final aortic
diameter in the TIMP-2/ mice was, however, less than
the final diameter of the wild-type controls (P  .0159;
Table II). There was no change in the aortic diameter of the
sham mice (NaCl substituted for CaCl2). If the primary
physiologic role of TIMP-2 were MMP inhibition, one
would expect augmentation of the aneurysm in its absence.
In contrast, we observed moderate inhibition in the ab-
sence of TIMP-2, showing that overall, it promotes aneu-
rysm formation.
Histologic changes. Compared with mice treated
with NaCl, in which the aorta appeared normal (Fig 3, a
and b), connective staining of aortic sections from the
CaCl2-treated wild-type and TIMP 2
/ mice revealed a
similar degree of disruption and fragmentation of the me-
dial elastic lamellae (Fig 3, c and d). There were no discern-
ible differences on trichrome staining between wild-type
and TIMP 2/ mice.
MMP-2 activation. The processing of MMP-2 in
mouse aortas was examined by gelatin zymography (Fig 4,
b). Processed MMP-2 was identified not only in the aortic
extracts of wild-type mice, but also in the extracts of TIMP
2/ mice. This is consistent with the observations of
Morrison et al,19 who have demonstrated some MMP-2
processing through pathways independent of TIMP-2.
That TIMP-2 has a primary role in MMP-2 activation was
shown by the significant decrease in levels of processed
MMP-2 from TIMP-2/ mice compared with wild-type
mice (Fig 4, a; P  .0183). These findings suggest that the
attenuated aortic dilatation seen in the TIMP-2/ defi-
cient mice is attributable to the lesser degree of MMP-2
activation (Table II).
DISCUSSION
Aneurysmal degeneration is a common and potentially
fatal disease that has major effect on the health care of the
elderly. Even though new options are being explored,
treatment of AAA is mechanical, as it has been for the past
50 years. Aneurysm research in the past decade focused on
characterization of tissues, with more recent advances com-
ing through the use of animal models that reproduce many
aspects of human disease. The etiology of AAA is slowly
coming to light. Disruption of the orderly elastin and
collagen structure in the media and adventitia is one of the
principal characteristics of AAA. Past studies of human
abdominal aortic tissue4,20-22 and more recent investiga-
tions using animal models of AAA1,2,23 have shown that
these matrix changes are mediated by MMPs, particularly
MMP-2 and MMP-9.
MMP activity is normally regulated through a series of
steps including synthesis, activation of the latent enzyme,
and inhibition of the active enzyme by specific TIMPs. An
altered balance between MMPs and their inhibitors is
WT co
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are ubiquitously produced in the extracellular aortic milieu,
and unstimulated smoothmuscle cells express high levels of
TIMP-1 and TIMP-2 messenger RNA and protein.24
TIMP-1 and TIMP-2 have been extensively studied in the
aorta. TIMP-1 can inhibit MMP-1, -9, and -3 activity.25 A
number of studies have found an increase in TIMP-1 levels
in AAA.4,26 Overexpression of TIMP-1 in one model of
AAA inhibited aneurysm formation and led to the accumu-
lation of matrix proteins.27 Further studies using TIMP-1
gene knockout mice showed that deletion of TIMP-1
Table II. Changes in aortic diameter in C57BL/6 WT co
NaCl or CaCl2
Variable
WT
NaCl
n 11
Pretreatment (m) 535  8.3 53
Posttreatment (m) 551  7.7 88
% Increase 3.4
WT, Wild type; TIMP, tissue inhibitor of metalloproteinase.
Aortic diameters were measured before NaCl or CaCl2 application (pretre
expressed as mean  SE. The percentage increase represents the percentage
*P  .01, paired Student t test, comparing the pretreatment value with the
†P  .05, ANOVA, final diameter of CaCl2 TIMP-2/ vs CaCl2-treated
a c
b d
NaCl
Fig 3. Histologic changes in mouse aorta by trichrom
C57BL/6 wild-type (WT) controls (a and c) and C57BL
d) mice is shown. The staining is representative of thre
profound in the CaCl2-treated WT mice. There is also saugments aneurysm formation.10,11We have demonstrated in a previous study thatMMP-2
is required for aneurysm formation in the CaCl2 murine
aneurysm model.2 Aneurysm formation and matrix degra-
dation are completely abrogated by the targeted deletion of
MMP-2. TIMP-2 is a 22-kd protein that has a curious dual
role in regulating MMP-2. At low concentrations, TIMP-2
forms a ternary complex withMT1-MMP and pro–MMP-2
on the cell surface. Modeling studies suggest that this
results in binding of an additional pro–MMP-2 molecule.
An adjacent TIMP-free active MT1-MMP molecule then
activates the pro–MMP-2 to MMP-2. At significantly
ls and C57BL/6 TIMP-2/ mice after treatment with
TIMP-2/
l2 NaCl CaCl2
7 11
8.3 510  14.3 502  5.4
14.8* 547  21.1 757  14.7*†
3 7.2 51.1
t) and before death (posttreatment). Measurements of aortic diameter are
ge compared with the pretreatment diameter.
diameter.
ntrol mice.
WT
TIMP-2-/-
CaCl2
aining. One example of NaCl or CaCl2 treatment of
sue inhibitor of metalloproteinase (TIMP)-2/ (b and
five samples with similar results. The matrix damage is
ant matrix destruction in the TIMP-2/ mice.ntro
CaC
11
3 
7 
67.
atmen
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finale st
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e tohigher concentrations, TIMP-2 blocks MT1-MMP–medi-
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MMP-2 activity.28 Studies have demonstrated that
TIMP-2 is increased, unchanged, and decreased in AAA
tissues.16,20,22,29-31 However, as both a coactivator of pro–
MMP-2 and a TIMP-2, no information is available to date
regarding the net effect (augmentation or inhibition) of
TIMP-2 on aneurysm formation.
In this study, the role of TIMP-2 in AAAwas studied by
using TIMP-2–deficient mice. In the absence of TIMP-2,
mice developed significant aortic enlargement in response
to CaCl2 treatment. The aneurysms, however, were signif-
icantly smaller than those that developed in the corre-
sponding wild-type controls. This is in contrast to studies
using the elastase model of aneurysms with TIMP-1–defi-
cient mice. The TIMP-1–deficient mice developed larger
aneurysms than the wild-type control mice, thus confirm-
ing that TIMP-1 acts primarily as an inhibitor ofMMPs. To
evaluate the mechanism of the effects of TIMP-2, gelatin
zymography was used to assess the proportion of latent and
processedMMP-2. This showed a decrease in the processed
NaCl NaClCaCl2 CaCl2
WT TIMP-2-/-
ProMMP-2
Processed MMP-2
ProMMP-9
Processed MMP-982.2
64.2
MW
(kD)
a
b
Fig 4. Gelatin zymographic analysis of latent and processed ma-
trix metalloproteinase (MMP)-2 in the mouse aorta. Six weeks
after 0.9% NaCl or 0.25 mol/L CaCl2 treatment, mouse aortas
from C57BL/6 (wild-type; WT) and tissue inhibitor of metallo-
proteinase (TIMP)-2/ mice were harvested. Aortic proteins
were extracted and separated by electrophoresis on a 10% sodium
dodecylsulfate-polyacrylamide gel electrophoresis containing 0.8%
gelatin (b). Band intensities (gelatinolytic activities) were mea-
sured by a densitometer. The percentage of processedMMP-2 and
total MMP-2 in WT (n  4) and TIMP-2/ (n  4) mice was
analyzed (P  .0183) (a). The gel is representative of three
independent experiments with similar results. MW, Molecular
weight.or active form of MMP-2 in TIMP-2–deficient mice. Thedecrease in active MMP-2 is consistent with the known
participation of the TIMP-2 molecule in the activation of
MMP-2. There is some MMP-2 activation in TIMP-2–
deficient mice, thus illustrating that alternative, TIMP-2–
independent, pathways for MMP-2 activation are opera-
tive. This finding is consistent with the observations of
Morrison et al,19 who observed that MMP-2 could be
activated through an alternative pathway involving MT2-
MMP. It is also possible in knockoutmice that theremay be
compensatory changes, such as the upregulation of other
MT-MMPs, that could affect the phenotype of the mouse.
This study was conducted to determine the net effect
(promotion vs inhibition of matrix destruction) of TIMP-2
in vivo in a model of AAA. If the primary effect of TIMP-2
were similar to the MMP inhibitory effects of TIMP-1, we
would have observed larger aneurysms in CaCl2-exposed
TIMP-2/ mice compared with wild-type control mice.
Instead, we observed that the dilatation and matrix damage
of CaCl2-treated TIMP-2
/ mice were significantly less
than those of CaCl2-treated wild-type mice. That a small
proportion ofMMP-2 in the TIMP-2/mice is processed
to the active form confirms that alternative TIMP-2–inde-
pendent pathways were operative in vivo. Even though
there was only one fourth as much active MMP-2 in the
CaCl2-treated TIMP-2
/ mice, there was significant di-
latation and matrix damage, thus indicating the efficiency
of processed MMP-2 against structural matrix macromole-
cules of the aorta. In vitro studies have shown that TIMP-2
can act as both a promoter and an inhibitor of matrix
destruction in a concentration-dependent manner through
activation ofMMP-2 or inhibition of activeMMP-2. In this
study, using amurinemodel of aortic aneurysm, we showed
that, in vivo, TIMP-2 acts primarily to promote rather than
inhibit matrix degradation. This effect seems to be medi-
ated through the processing of latent MMP-2 to its active
form.32
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